1.All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells
Yundeok KIM ; Hoi-Kyung JEUNG ; June-Won CHEONG ; Jaewoo SONG ; Soo Han BAE ; Jong In LEE ; Yoo Hong MIN
Yonsei Medical Journal 2020;61(9):762-773
Purpose:
Pharmacological inhibition of mutant isocitrate dehydrogenase (IDH) reduces R-2-hydroxyglutarate (2-HG) levels and restores cellular differentiation in vivo and in vitro. The IDH2 inhibitor enasidenib (AG-221) has been approved by the FDA as a first-in-class inhibitor for the treatment of relapsed or refractory (R/R) IDH2-mutant acute myeloid leukemia (AML). In this study,the effects of a combination of all-trans retinoic acid (ATRA) and AG-221 on AML cell differentiation was explored, along with the mechanisms employed by IDH2-mutant cells in AML. Materials and Methods: We treated the human AML cell line, IDH2-mutant-TF-1, and primary human AML cells carrying IDH2 mutation with 30 μM AG-221 and 100 nM ATRA, alone or in combination.
Results:
Combined treatment with AG-221 and ATRA inhibited 2-HG production and resulted in synergistic effects on differentiation among IDH2-mutant AML cells and primary AML cells expressing IDH2 mutation. Combined treatment with AG-221 and ATRA altered autophagic activity. AG-221 and ATRA treatment-induced differentiation of IDH2-mutant AML cells was associated with autophagy induction, without suppressing autophagy flux at maturation and degradation stages. A RAF-1/MEK/ERK pathway was founded to be associated with AG-221 and ATRA-induced differentiation in IDH2-mutant AML cells. IDH-associated changes in histone methylation markers decreased after AG-221 and ATRA combination treatment.
Conclusion
Our preliminary evidence indicates that the addition of ATRA to treatments with IDH2 inhibitor may lead to further improvements or increases in response rates in IDH2-mutant AML patients who do not appear to benefit from treatments with IDH2 inhibitor alone.
2.Comparative pharmacokinetics between two tablets of tramadol 37.5 mg/acetaminophen 325 mg and one tablet of tramadol 75 mg/acetaminophen 650 mg for extended-release fixed-dose combination
Hyun Chul KIM ; Deok Yong YOON ; SeungHwan LEE ; In-Jin JANG ; Jang Hee HONG ; JaeWoo KIM
Translational and Clinical Pharmacology 2022;30(2):112-119
An extended-release (ER) fixed-dose combination (FDC) of tramadol 37.5 mg/acetaminophen 325 mg was developed due to the demand for varying dosages. This study aimed to evaluate the pharmacokinetics (PKs) for two tablets of the new developed tramadol 37.5 mg/acetaminophen 325 mg ER FDC (DW-0920, Wontran Semi ER®) as test formulation compared to one tablet of the tramadol 75 mg/acetaminophen 650 mg ER FDC (DW-0919, Wontran ER®) as reference formulation. A randomized, open-label, 2-way crossover study was conducted in 30 healthy subjects. Subjects were orally administered one of 2 formulations followed by an alternate formulation with a 7-day washout period. Blood samples were collected up to 36 hours post-dose. Plasma concentrations of tramadol and acetaminophen were determined using a validated high-performance liquid chromatography with tandem mass spectrometric method. The geometric mean ratios (GMRs) and their 90% confidence intervals (90% CIs) of test formulation to reference formulation were calculated for the maximum plasma concentration (Cmax) and the area under the plasma concentration-time curve from zero to the last measurable time point (AUClast). The PK profiles of 2 formulations were comparable. The GMRs (90% CI) of Cmax and AUClast for tramadol were 1.086 (1.047–1.127) and 1.008 (0.975–1.042), respectively. The corresponding values for acetaminophen were 0.956 (0.897–1.019) and 0.986 (0.961–1.011), respectively. All the values were within the bioequivalence range of 0.80–1.25. Two tablets of DW-0920 were comparable to one tablet of DW-0919. The DW-0920 may be used for optimal pharmacotherapy for pain control with a lower dose.
3.BIRB 796 has Distinctive Anti-inflammatory Effects on Different Cell Types.
Soyoon RYOO ; Jida CHOI ; Jaemyung KIM ; Suyoung BAE ; Jaewoo HONG ; Seunghyun JO ; Soohyun KIM ; Youngmin LEE
Immune Network 2013;13(6):283-288
The pro-inflammatory cytokines tumor necrosis factor-alpha (TNFalpha) and interleukin (IL)-1beta are crucial mediators involved in chronic inflammatory diseases. Inflammatory signal pathways regulate inflammatory cytokine expression-mediated by p38 mitogen activated protein kinase (p38MAPK). Therefore, considerable attention has been given to p38MAPK as a target molecule for the development of a novel anti-inflammatory therapeutics. BIRB 796, one of p38MAPK inhibitor, is a candidate of therapeutic drug for chronic inflammatory diseases. In this study, we investigated the effect of BIRB 796 on inflammatory cytokine productions by lipopolysaccharide (LPS) in different immune cell types. BIRB 796 reduced LPS-mediated IL-8 production in THP-1 cells but not in Raw 264.7 cells. Further analysis of signal molecules by western blot revealed that BIRB 796 sufficiently suppressed LPS-mediated phosphorylation of p38MAPK in both cell types whereas it failed to block inhibitor of kappa B (I-kappaB) degradation in Raw 264.7 cells. Taken together, these results suggest that the anti-inflammatory function of BIRB 796 depends on cell types.
Blotting, Western
;
Cytokines
;
Interleukin-8
;
Interleukins
;
Phosphorylation
;
Protein Kinases
;
Signal Transduction
;
Tumor Necrosis Factor-alpha
4.The Relationship between Obstructive Sleep Apnea and Metabolic Syndrome in Adult.
Min Jeong PARK ; Insik SONG ; Jaewoo JOO ; Tae Min KIM ; Hee Chul YUN ; Joon Hyuk YOO ; Seung No HONG ; Seung Hoon LEE
Journal of Rhinology 2016;23(2):97-101
BACKGROUND AND OBJECTIVES: The prevalence of obstructive sleep apnea (OSA) and metabolic syndrome (MS) is increasing and those have been recognized as potential risk factors for cardiovascular disease in adults. The aim of this study is to investigate the association between obstructive sleep apnea syndrome and metabolic syndrome. MATERIALS AND METHODS: We enrolled 127 adults who were evaluated as having OSA. Each subject underwent overnight polysomnography to identify OSA based on the apnea-hypopnea index (AHI); OSA was diagnosed when AHI≥5, and subjects with AHI<5 were classified as the control group. MS was defined according to the Adult Treatment Panel (ATP) III criteria. RESULTS: Among 127 participants, 105 subjects were diagnosed with OSA. The mean age and smoker percentage showed differences between the OSA and control group. The prevalence of MS was significantly higher in the OSA group compared to the control group. As the severity of OSA increases, the prevalence of MS also increase. CONCLUSIONS: The MS is significantly related to the OSA in adults. Therefore, we suggest that patient with OSA should be screened to identify the presence of MS.
Adult*
;
Cardiovascular Diseases
;
Humans
;
Polysomnography
;
Prevalence
;
Risk Factors
;
Sleep Apnea, Obstructive*
5.Association between Promoter Polymorphisms of TFF1, TFF2, and TFF3 and the Risk of Gastric and Diffuse Gastric Cancers in a Korean Population.
Eun Heui JIN ; Sang Il LEE ; Jaewoo KIM ; Eun Young SEO ; Su Yel LEE ; Gang Min HUR ; Sanghee SHIN ; Jang Hee HONG
Journal of Korean Medical Science 2015;30(8):1035-1041
Gastric cancer is one of the most common cancers in the world. The aims of this study were to evaluate the association between polymorphisms in TFF gene family, TFF1, TFF2, and TFF3 and the risk of gastric cancer (GC) and GC subgroups in a Korean population via a case-control study. The eight polymorphisms in TFF gene family were identified by sequencing and genotyped with 377 GC patients and 396 controls by using TaqMan genotyping assay. The rs184432 TT genotype of TFF1 was significantly associated with a reduced risk of GC (odds ratio, [OR) = 0.45; 95% confidence interval, [CI] = 0.25-0.82; P = 0.009), more protective against diffuse-type GC (OR = 0.20; 95% CI = 0.05-0.89; P = 0.035) than GC (OR = 0.34; 95% CI = 0.14-0.82; P = 0.017) in subjects aged < 60 yr, and correlated with lymph node metastasis negative GC and diffuse-type GC (OR = 0.44; 95% CI = 0.23-0.86; P = 0.016 and OR = 0.20; 95% CI = 0.05-0.87; P = 0.031, respectively). In addition, a decreased risk of lymph node metastasis negative GC and diffuse-type GC was observed for rs225359 TT genotype of TFF1 (OR = 0.46, 95% CI = 0.24-0.88; P = 0.020 and OR = 0.21, 95% CI = 0.05-0.88; P = 0.033, respectively). These findings suggest that the rs184432 and rs225359 polymorphisms in TFF1 have protective effects for GC and contribute to the development of GC in Korean individuals.
Adult
;
Aged
;
Biomarkers, Tumor/*genetics
;
Female
;
Genetic Markers/genetics
;
Genetic Predisposition to Disease/epidemiology/genetics
;
Humans
;
Incidence
;
Male
;
Middle Aged
;
Peptides/*genetics
;
Polymorphism, Single Nucleotide/genetics
;
Promoter Regions, Genetic/genetics
;
Reproducibility of Results
;
Republic of Korea/epidemiology
;
Risk Assessment/methods
;
Sensitivity and Specificity
;
Stomach Neoplasms/*epidemiology/*genetics
;
Tumor Suppressor Proteins/*genetics
6.Comparison of loss of response between anti-tumor necrosis factor alone and combined use with immunomodulators in patients with inflammatory bowel disease
Seung Wook HONG ; Jaewoo PARK ; Hyuk YOON ; Hye Ran YANG ; Cheol Min SHIN ; Young Soo PARK ; Nayoung KIM ; Dong Ho LEE ; Joo Sung KIM
The Korean Journal of Internal Medicine 2021;36(Suppl 1):S9-S17
Background/Aims:
Combination therapy with immunomodulators (IMMs) was proposed as a strategy to prevent the development of loss of response (LOR) to anti-tumor necrosis factor (TNF) for patients with inflammatory bowel disease (IBD). However, the effect is unclear in patients already exposed to IMMs. The aim of this study was to evaluate whether combination therapy with IMMs is superior to monotherapy for prevention of LOR to anti-TNF.
Methods:
This was a retrospective study of patients in Seoul National University Bundang Hospital with IBD between January 2009 and October 2018. LOR was defined as clinical deterioration after maintenance of anti-TNF for at least 6 months. We investigated the difference in incidence of LOR to anti-TNF between the monotherapy and combination groups. We additionally assessed factors affecting LOR development to anti-TNF.
Results:
A total of 116 patients with IBD were included in this study (monotherapy 61 patients; combination 55 patients). Overall, LOR to anti-TNF occurred in 31 patients during the follow-up period. The combination of an anti-TNF agent and IMM showed no significant difference in the incidence of LOR compared to anti-TNF agent monotherapy (hazard ratio [HR], 1.64; 95% confidence interval [CI], 0.786 to 3.148; p = 0.182). Female sex was significantly associated with the development of LOR to anti-TNF (HR, 3.032; 95% CI, 1.467 to 6.268; p = 0.003).
Conclusions
Anti-TNF and IMM combination therapy did not prove efficacious in preventing the development of LOR in IBD patients. Female sex was associated with the development of LOR to anti-TNF; further studies are required to confirm these results.
7.Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target
Jaewoo HONG ; Hyunjhung JHUN ; Yeo-Ok CHOI ; Afeisha S. TAITT ; Suyoung BAE ; Youngmin LEE ; Chang-seon SONG ; Su Cheong YEOM ; Soohyun KIM
Immune Network 2021;21(1):e8-
The global crisis caused by the coronavirus disease 2019 (COVID-19) led to the most significant economic loss and human deaths after World War II. The pathogen causing this disease is a novel virus called the severe acute respiratory syndrome coronavirus 2 (SARSCoV-2). As of December 2020, there have been 80.2 million confirmed patients, and the mortality rate is known as 2.16% globally. A strategy to protect a host from SARS-CoV-2 is by suppressing intracellular viral replication or preventing viral entry. We focused on the spike glycoprotein that is responsible for the entry of SARS-CoV-2 into the host cell. Recently, the US Food and Drug Administration/EU Medicines Agency authorized a vaccine and antibody to treat COVID-19 patients by emergency use approval in the absence of long-term clinical trials. Both commercial and academic efforts to develop preventive and therapeutic agents continue all over the world. In this review, we present a perspective on current reports about the spike glycoprotein of SARS-CoV-2 as a therapeutic target.
8.Neutrophilic Granule Protein Is a Novel Murine LPS Antagonist
Jaewoo HONG ; Peng QU ; Todd R WUEST ; Haishan HUANG ; Chuanshu HUANG ; P Charles LIN
Immune Network 2019;19(5):e34-
Neutrophilic granule protein (NGP) was previously reported as a granular protein of neutrophils in mouse, but the function has not been known clearly. We found the presence of the possible signal peptide in NGP and validated this protein is circulating in the bloodstream. In our findings, NGP is being modified post-translationally in Golgi apparatus and endoplasmic reticulum, which is a universal character of secretory molecules with a signal peptide. The secreted NGP protein could be detected both in vitro and in vivo. NGP has sequence similarity with an antimicrobial protein cathelicidin, and we observed the aspect of inflammation of NGP. Interestingly, NGP interacts with the complex of LPS and LPS binding protein (LBP). This interaction blocks the binding of the complex of LPS and LBP to TLR4 and the downstream inflammatory signals. Furthermore, the inhibitory function of NGP against the inflammatory effect of LPS could be observed in both in vitro and in vivo. With these findings, we report NGP is a novel secretory protein to mask LPS and inhibit its function.
Animals
;
Carrier Proteins
;
Cytokines
;
Endoplasmic Reticulum
;
Golgi Apparatus
;
In Vitro Techniques
;
Inflammation
;
Lipopolysaccharides
;
Masks
;
Mice
;
Neutrophils
;
Protein Binding
;
Protein Sorting Signals
9.Bioequivalence of Two Erlotinib Formulations in Healthy Volunteers.
Jaewoo KIM ; Eun Heui JIN ; Youn Woong CHOI ; Byung Gu MIN ; Byung Hoon LEE ; Jin Seong CHUNG ; Kyu Yeol NAM ; Won Tae JUNG ; Soo Hwan KIM ; Hye J LEE ; Jang Hee HONG
Journal of Korean Society for Clinical Pharmacology and Therapeutics 2013;21(2):159-165
BACKGROUND: Erlotinib is a tyrosine kinase inhibitor prescribed for the treatment of non-small cell lung cancer and pancreatic cancer. The aim of this study was to compare the safety and pharmacokinetics (PK) of a generic (test) formulation of erlotinib with those of a reference formulation in healthy volunteers. METHODS: A randomized, open-label, single-dose two-treatment, two-period, two-sequence, crossover study was conducted in Clinical Trials Center, Chungnam National University Hospital with 40 healthy men. Subjects orally received either one 150 mg tablet of the test or the corresponding dose of the reference, and crossover phases were separated by 14-day washout. Plasma samples were collected up to 72 hr post-dose. Plasma erlotinib concentrations were determined by liquid chromatography-tandem mass spectrometry. PK parameters were calculated by non-compartmental analysis. The safety was monitored throughout the study. RESULTS: A total of 21 cases of adverse events were reported. They are mild and relieved without an intervention. There was no serious adverse event. Median times to peak concentration of two formulations were 3.0. Means [SD] for peak concentration (Cmax) and area under the plasma concentration-time curve (AUC) of the test were 1,298 [346] microg/L and 25,318 [7,668] hrxmicrog/L. Those of the reference were 1,193 [378] microg/L and 24,853 [8,419] hrxmicrog/L. Geometric mean ratios (90% confidence intervals) for the test to the reference were 1.10 (1.02-1.18) for Cmax and 1.02 (0.97-1.09) for AUC. CONCLUSION: Two formulations were safe and well-tolerated. PK findings suggest that the test formulation is equivalent to the reference in terms of pharmacokinetics.
Area Under Curve
;
Carcinoma, Non-Small-Cell Lung
;
Chungcheongnam-do
;
Cross-Over Studies
;
Erlotinib Hydrochloride
;
Healthy Volunteers*
;
Humans
;
Male
;
Mass Spectrometry
;
Pancreatic Neoplasms
;
Pharmacokinetics
;
Plasma
;
Protein-Tyrosine Kinases
;
Therapeutic Equivalency*
10.Unexpected Appendiceal Pathologies and Their Changes With the Expanding Use of Preoperative Imaging Studies.
Hong Yeol YOO ; Jaewoo CHOI ; Jongjin KIM ; Young Jun CHAI ; Rumi SHIN ; Hye Seong AHN ; Chang Sup LIM ; Hae Won LEE ; Ki Tae HWANG ; In Mok JUNG ; Jung Kee CHUNG ; Seung Chul HEO
Annals of Coloproctology 2017;33(3):99-105
PURPOSE: The preoperative diagnosis of acute appendicitis is often challenging. Sometimes, pathologic results of the appendix embarrass or confuse surgeons. Therefore, more and more imaging studies are being performed to increase the accuracy of appendicitis diagnoses preoperatively. However, data on the effect of this increase in preoperative imaging studies on diagnostic accuracy are limited. We performed this study to explore unexpected appendiceal pathologies and to delineate the role of preoperative imaging studies in the diagnosis of acute appendicitis. METHODS: The medical records of 4,673 patients who underwent an appendectomy for assumed appendicitis between 1997 and 2012 were reviewed retrospectively. Pathological results and preoperative imaging studies were surveyed, and the frequencies of pathological results and preoperative imaging studies were investigated. RESULTS: The overall rate of pathology compatible with acute appendicitis was 84.4%. Unexpected pathological findings, such as normal histology, specific inflammations other than acute appendicitis, neoplastic lesions, and other pathologies, comprised 9.6%, 3.3%, 1.2%, and 1.5%, respectively. The rate of unexpected pathological results was significantly reduced because of the increase in preoperative imaging studies. The decrease in normal appendices contributed the most to the reduction while other unexpected pathologies did not change significantly despite the increased use of imaging studies. This decrease in normal appendices was significant in both male and female patients under the age of 60 years, but the differences in females were more prominent. CONCLUSION: Unexpected appendiceal pathologies comprised 15.6% of the cases. Preoperative imaging studies reduced them by decreasing the negative appendectomy rate of patients with normal appendices.
Appendectomy
;
Appendicitis
;
Appendix
;
Diagnosis
;
Female
;
Humans
;
Inflammation
;
Male
;
Medical Records
;
Pathology*
;
Retrospective Studies
;
Surgeons